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CARDIOGENIC PULMONARY EDEMA ET CAUSA HYPERTENSION  




Acute pulmonary edema is one of the emergency conditions that require immediate management. Acute pulmonary 
edema occurs because of the underlying disease such as hypertension, coronary heart disease, and other heart 
diseases. From January 2018 to November 2018, there were 13,332 patients who came to the ED at the UKI 
Hospital, 99 patients with acute cardiogenic pulmonary edema. Of the 99 patients, there were 39% male sex data, 
60% female, 36-45 years old age data 8%, 46-55 years 20%, 56-65 years 41%,≥ 66 years 30%, the cause of acute 
pulmonary edema due to hypertension (52%), coronary heart disease (42.6%), and other cardiovascular diseases 
(5.4%), mortality (8%).
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6 million inhabitants. This is a large 
number that needs attention from nurses 
in caring for pulmonary edema clients in 
a comprehensive bio, psycho, social and 
spiritual way. 1
 Pulmonary edema disease was first 
discovered in Indonesia in 1971. Since 
then the disease has spread to various 
regions, so that until 1980 all provinces 
in Indonesia. In Indonesia, the largest 
incidence occurred in 1998 with the 
incidence rate (IR) = 35.19 per 100,000 
population and CFR = 2%. In 1999 IR 
decreased sharply by 10.17%, but in 
subsequent years IR tended to increase, 
namely 15.99 (2000), 19.24 (year 2002) 
and 23.87 (year 2003). Acute cardiogenic 
pulmonary edema is pulmonary edema 
that often occurs and has a detrimental 
and lethal impact with a mortality rate of 
10-20% . 4
1.1 Formulation Problem
Based on the background of the 
problem above, the problem formulation 
of this study is what is the prevalence 
of sufferers of acute pulmonary edema 
in the Emergency Unit of the General 




To find out the prevalence of acute 
pulmonary edema in the Emergency 
Unit of the Indonesian Christian General 
Hospital in 2018.
2. Special Purpose
a.  This is to determine the 
prevalence of acute pulmonary 
edema
BB
b. This is to determine the risk 
factors in patients with acute 
1. Introduction
Pulmonary edema is an accumulation 
of fluid in the lungs that occurs suddenly. 
This can be caused by high intravascular 
pressure (cardiac pulmonary edema) or 
due to increased capillary permeability 
(non-cardiac pulmonary edema) which 
results in rapid extravasation of fluid 
in the alveoli resulting in impaired air 
exchange and resulting in hypoxia. 
Pulmonary edema is an emergency with 
a high mortality rate. 1
Hypertension or an increase in 
blood pressure is a chronic disease and 
has always been a problem in public 
health in general, both in developed and 
developing countries.
Hypertension is also known as 
the “silent killer” which is often 
asymptomatic, but can damage several 
important organs such as the heart, brain, 
and kidneys. 1
 Based on the body organs that are 
the target of damage from hypertension, 
uncontrolled hypertension can increase 
the risk of developing it. Dead. Statistics 
show that hypertensive complications 
cause an estimated 9.4 million deaths 
worldwide each year. 2
Based on data from Riskesdas in 
2013, the prevalence of hypertension at 
age ≥18 years in Indonesia was 25.8%. 
In DKI Jakarta alone, the prevalence of 
hypertension based on a diagnosis of 
health personnel obtained by measuring 
blood pressure reached 20% . 3 According 
to a study in 1994, there were 74.4 
million people with pulmonary edema in 
the world. In the UK about 2.1 million 
sufferers pulmonary edema which 
needs treatment and comprehensive 
surveillance. In the United States an 
estimated 5.5 million people suffer from 
pulmonary edema. In Germany about 
3
2.2 Classification and Etiology
Pulmonary edema can be classified 
as cardiogenic pulmonary edema and 
non-cardiogenic pulmonary edema. 
Cardiogenic pulmonary edema is 
caused by an increase in pulmonary 
capillary hydrostatic pressure which 
can occur due to excessive perfusion 
from both infusion, blood, and other 
blood products and fluids, while non-
cardiogenic pulmonary edema is caused 
by increased pulmonary capillary 
permeability, among others, post 
lung transplantation and expansion of 
pulmonary edema. including ischemia-
reperfusion-mediated injury.
Pulmonary edema is usually the 
result of increased pulmonary capillary 
vascular pressure and alveolar capillary 
permeability. Pulmonary edema due to 
increased lung cancer permeability is 
often called acute respiratory distress 
syndrome (ARDS).
Although the causes of cardiogenic 
and non-cardiogenic pulmonary edema 
are different, they both have a similar 
clinical appearance that makes diagnosis 
difficult. Appropriate therapy is needed 
to save patients from further damage due 
to fluid balance disorders in the lungs.
Approximately 90% of hypertension 
sufferers are classified as primary or 
essential hypertension when the cause 
of hypertension cannot be identified 
(idiopathic). Meanwhile the other 5-10% 
are classified
 as secondary hypertension, which 
results from an underlying disease such 
as kidney disorders, use of drugs or 
hormonal disorders. 1,5
pulmonary edema such as 
cardiac (hypertension, coronary 
heart disease) and non-cardiac 
(chronic renal failure).
1.3 Benefits
1 For the author
The results of this study can be used 
as additional information and knowledge 
about pulmonary edema and the authors 
note the importance of proper prevention 
and management in pulmonary edema 
patients.
2 For Health Services
The results of this study can be used 
by all health care workers to realize 
the importance of prevention, early 
diagnosis and proper management of 
patients with pulmonary edema in order 
to prevent complications.
3 For Education
The results of this study can be used 
as reference data for further research 




Pulmonary edema is defined as a 
condition where there is movement 
of fluid from the pulmonary vascular 
to the interstitial and pulmonary 
alveoli. In pulmonary edema there 
is an accumulation of serous fluid or 
serosanguinosa in the interstitial space 
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Table 1. Difference between cardiogenic and non-cardiogenic pulmonary edema 1
The classification of hypertension based on JNC VII 2003 can be seen in the following table:
Table 2. Classification of hypertension5
Classification Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg)
Normal < 120 dan < 80
Pre-hipertensi 120 – 139 atau 80 -89
Hipertensi tingkat 1 140 –159 atau 90 – 99
Hipertensi tingkat 2 ≥ 160 atau ≥ 100
Hipertensi tingkat 3 ≥ 180 atau ≥ 110
Isolated systolic hypertension ≥ 140 dan <90
2.3 Pathophysiology
Under normal conditions in the 
lungs there is a continuous flow of 
intravascular fluid and protein to 
the interstitial tissue and back to the 
bloodstream system through the lymph 
channels which comply with Starling’s 
law 6,7,8,9
Q = K (Pc-Pt) - d (c-t)
Q : Flow of liquid 
K : Constant
Pc : Hydrostatic pressure in capillaries
Pt : Hydrostatic pressure at interstitium
D : Reflection coefficient
C : Oncotic pressure in the capillaries
Q : Oncotic pressure in the interstitium
Jv : LpS {(Pc – Pi) – αd ( πc – πi)}
Jv  : Fluid filtration rate (volume flow) 
across the microvascular barrier
Lp : Hydraulic conductivity 
(permeability)
S : Surface area of the barrier
Pc : Microvascular hydrostatic pressure
Pi : Peri microvascular hydrostatic 
pressure
πc  : Microvascular plasma 
colloidosmotic/oncotic pressure
5
2. Hypoxemia and increased fluid 
in the lungs cause pulmonary 
vasoconstriction, thereby increasing 
the right ventricular pressure, 
which through the ventricular 
interdependence mechanism will 
further reduce left ventricular 
function.
12 mmHg insufficiency and a 
plasma colloid osmotic pressure of 
28 mmHg. The incident will create 
a vicious cycle which continues 
to be worsened by the following 
processes: : 7,8
3.  Increased circulation causes acidosis, 
which worsens heart function.
The discharge of edematous 
fluid from the pulmonary alveoli 
depends on active transport of Na 
+ and Cl ions across the epithelial 
barrier contained in the apical 
membrane of alveolar type I and 
II epithelial cells and the distal 
airway epithelium. Na + ions are 
actively transported out into the 
interstitial space by the action of 
Na / K-ATPase which is located on 
the basolateral membrane of type 
II cells. Water passively follows, 
possibly through aquaporins, which 
are drains to type I cells. 7,8,9 
There are three physiological 
levels of accumulation in 
cardiogenic pulmonary edema:
1. Grade I: Fluid and colloids 
move from the pulmonary 
capillaries to the pulmonary 
interstitials but there is an 
increase in fluid out of the 
lymphatic flow
2.  Level II: The pumping capacity 
of the lymphatic system has 
been exceeded so that fluids and 
colloids begin to accumulate in 
πi : Peri microvascular plasma 
colloidosmotic/oncotic pressure
αd : Average osmotic reflection 
coefficient of the barrier
Pulmonary edema occurs when more 
fluid is filtered by the microvascular 
walls than can be removed, which results 
in the alveoli being filled with fluid so 
that gas exchange is not possible. The 
determining factors that play a role 
here are differences in hydrostatic and 
oncotic pressures in the capillary and 
intersitic lumen, permeability of endolter 
cells to water, solutions, and the size of 
molecules such as plasma proteins. An 
imbalance of one or more of the above 
factors will cause pulmonary edema7. 
In cardiogenic pulmonary edema 
(volume overload edema) an increase in 
hydrostatic pressure in the pulmonary 
capillaries leads to an increase in 
transvascular filtration. When the 
interstitial pressure of the lung is 
greater than the intrapleural pressure, 
the fluid moves towards the visceral 
pleura which causes pleural effusions. 
If the endothelial capillary permeability 
remains normal, the edema fluid leaving 
the circulation has a low protein content. 
The increase in pulmonary capillary 
hydrostatic pressure is usually caused 
by increased pressure in the pulmonary 
veins that occurs as a result of increased 
left ventricular end-diastolic pressure and 
left atrial pressure (> 25mmHg). Under 
normal circumstances the pulmonary 
capillary pressure is around 8-12
-
1. Pulmonary congestion causes 
desaturation and decreased 
myocardial oxygen supply, thus 
worsening heart function
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2. ECG shows heart problems such as 
left atrial enlargement, left ventricular 
enlargement, arrhythmias, ischemic 
myocardial infarction or infarction.
3. Echocardiography is performed to 
determine whether there is a decrease 
in the function of the left ventricle 
and valve abnormalities- heart valve.
4. Laboratory tests of cardiac enzymes 
are necessary to help establish a 
diagnosis of myocardial infarction. 
Increased levels of brain natriuretic 
peptide (BNP) in the blood in 
response to increased pressure in 
the ventricles, BNP levels > 500 pg 
/ ml can help diagnose cardiogenic 
pulmonary edema.
5. Blood gas analysis (AGDA) can 
showdecreased PO2 and PCO2 in 
the initial state but later in disease 
progression the PO2 decreased while 
PCO2 increased. In severe cases 
hypercapnia and respiratory acidosis 
are usually seen.
6. Right heart catheterization: 
Measurement of P pw (pulmonary 
capillary wedge pressure) through 
right heart catheterization is the gold 
standard for patients with cardiogenic 
pulmonary edema, which is around 
25- 35 mmHg while in patients with 
ARDS P pw 0-18 mmHg.
7. Edema fluid protein content: 
Measurement ratio
  Edema fluid protein concentration 
versus plasma protein can be used 
to differentiate cardiogenic and non-
cardiogenic pulmonary edema. The 
examination material is taken by 
suctioning pulmonary edema fluid 
through an endotracheal tube or 
bronchoscope and taking plasma. In 
cardiogenic pulmonary edema, the 
the interstitial spaces around 
the bronchioles, arterioles and 
venules.
3.  Level III: Increased fluid 
accumulation causes alveolar 
edema. At this stage, the gas 
exchange interruption begins.
2.4 Clinical Features
The clinical picture of pulmonary 
edema is that from the history, it is 
found that there is a sudden shortness 
of breath associated with a history of 
chest pain and a history of heart disease. 
The development of ray edema can 
be gradual or sudden as in the case of 
acute pulmonary edema. In addition, 
large amounts of sputum are frothy and 
pink in color. Other common symptoms 
that may be found are: fatigue, quicker 
feeling of shortness of breath during 
normal activity (dyspnea on exertion), 
rapid breathing (tachypnea), dizziness, 
or weakness. Low levels of blood 
oxygenation (hypoxia) may be detected 
in patients with pulmonary edema. On 
auscultation can hear abnormal lung 
sounds, such as crackles or crakles. 1,10
Supporting examinations are carried 
out to establish a diagnosis, namely:
1. Chest X-ray shows cardiomegaly (in 
patients with CHF) and alveolar 
edema with pleural effusions and 
bilateral infiltration in a butterfly 
pattern, pulmonary vascular and hilar 
cloudy features and the presence of 
interlobular Kerley B lines. Another 
feature associated with heart disease 
in the form of left ventricular dilation 
is common. Unilateral pleural 
effusions are also common and are 
associated with left heart failure.
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protein concentration is relatively 
higher (ratio> 0.7) because the 
nicrovascular barrier is reduced.
protein concentration of edema fluid 
is relatively low compared to plasma 
(ratio <0.6). In non-cardiogenic 
pulmonary edema the edema fluid 
Figure 1. Algorithm of steps to differentiate between cardiogenic and non-cardiogenic pulmonary edema. 
Source: Ware LB and Matthay MA, 2005
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induction of non-invasive 
ventilation in respiratory distress 
and metabolic disorders increases 
more rapidly than standard oxygen 
therapy but has no effect on short-
term mortality. Noninvasive 
ventilation with CPAP has been 
shown to reduce endotracheal 
intubation and mortality in patients 
with cardiogenic acute pulmonary 
dedema. According to the study of 
Agarwal et al, noninvasive pressure 
support ventilation (NIPSV) 
appears to be safe and efficacious 
as CPAP, rather than working with 
titration at fixed pressure. 12
The study of Winck et al. 
Supports the use of CPAP and 
non-invasive positive pressure 
ventilation (NPPV) in cardiogenic 
acute pulmonary edema. risk 
of acute myocardial infarction 
CPAP is considered to be the first 
intervention for NPPV that does not 
show better efficacy even in patients 
with more initial conditions, but is 
cheaper and easier to implement 
in clinical practice. Intubation and 
use of mechanical ventilation with 
positive end-expiratory pressure 
(PEEP) are required in severe cases. 
11 
 2.5.2 Medicines
a. Medicines that decrease preload
Nitroglycerin (NTG) can 
reduce preload effectively, 
quickly and the effect can 
be predicted. Intravenous 
administration of NTG is 
initiated with a low dose (20 
µg / min) and then increased 
gradually (maximum dose 200 
µg / min) .  1,11
2.5 Management
Pulmonary edema is a medical 
emergency that needs to be treated as 
soon as possible after a diagnosis is 
made. Primary management includes 
supportive treatment aimed primarily 
at maintaining lung function (eg gas 
exchange, organ perfusion), while 
the underlying causes should also be 
investigated and treated as soon as 
possible. 10
The principles of management 
include adequate oxygen administration, 
fluid restriction and maintaining 
cardiovascular function. Initial 
considerations are clinical evaluation, 
ECG, chest X-ray, and AGDA (blood 
gas analysis). 1
 2.5.1 Oxygen supplementation
Generalized hypoxemia in 
pulmonary edema is a major threat 
to the central nervous system, 
either in the form of decreased 
consciousness to coma or shock. 
Therefore oxygen supplementation 
is an important interventional 
therapy to increase gas exchange 
and decrease the work of breathing, 
optimize the lung functional unit 
as much as possible and reduce 
alveolar overdistention. 11
In mild cases, oxygen can be 
given with a nasal cannula or a face 
mask. Continuous positive airway 
pressure (CPAP) is especially 
helpful in patients with cardiogenic 
pulmonary edema. Masip et al 
found that use of CPAP decreases 
the need for intubation and increases 
mortality.
In patients with acute 
cardiogenic pulmonary edema, 
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3.2. Location and Time of Research
The research was conducted 
in the medical records of the UKI 
Hospital from January 2018 to 
December 2018
3.3. Population and Sample
The population and sample in 
this study were all patients with 
acute pulmonary edema who came 
to the UGD at RSU UKI in 2018.
3.4. Method of collecting data
The data were obtained 
from the medical records of UKI 
Hospital with consecutive sampling 
technique
 3.5. Operational definition
a. Acute pulmonary edema used 
according to ESC in 2012
b. Hypertension or increased blood 
pressure was used according to 
the JNC VIII criteria in 2013
c. Age is the length of time a 
patient lives until he comes to 
the UGD at RSU UKI which is 
expressed in years. If there is an 
excess of more than 6 months, 
it will be rounded up, if there 
are 6 months or less it will be 
rounded down
d. Gender is the gender of the 
patient, that is, male or female.
4. RESULTS AND DISCUSSION
4.1. General Characteristics
After conducting research 
through medical record data at UKI 
Hospital, 99 patients with acute 
cardiogenic pulmonary edema et 
causa hypertension came to the ER 
at UKI Hospital during the period 
Loop diuretics (furosemide) 
can reduce preload via two 
mechanisms, namely diuresis 
and venodilation. The dose 
of furosemide can be given 
orally 20 - 40 mg / day in mild 
conditions to 5 - 40 mg / hour by 
infusion in severe conditions.
Morphine sulfate is used to 
reduce preload at a dose of 3 mg 
intravenously and can be given 
repeatedly. 11
b. Medicines that are lower 
afterload 
Angiotension - converting 
enzyme inhibitors (ACE 
inhibitors) reduce after load, 
as well as improve stroke 
volume and cardiac output. 
Administration of intravenous 
(Enalapril 1.25mg) or 
sublingual (Captopril 25mg) 
will improve patient complaints. 
In a meta-analysis it was found 
that administration of ACE 
inhibitors will reduce mortality. 
1,11
c. Inotropic drugs
Inotropic drugs are given to 
cardiogenic pulmonary edema 
with hypotension, namely 
dobutamine 2 - 20mcg / kg / 
minute or dopamine 3 - 20 mcg 
/ kg / minute.
 
3. RESEARCH METHODOLOGY
3.1. Types of research
The research design used was 
descriptive method with cross 
sectional approach.
10
percentage of hypertension than 
men.16 Several factors have been 
studied that the role of the hormones 
estrogen and progesterone can 
help prevent damage to blood 
vessels due to oxidative stress and 
inflammation, and has an effect on 
the smooth muscle contraction of 
blood vessels. Estrogen itself can 
also increase the sensitivity of the 
pressure relationship and natriuresis 
and increase sodium excretion 6,7
January - November 2018. Of the 
total patients, 39 were male (39%). 
) while 61 women (60%). In this 
study, the prevalence of cardiogenic 
acute pulmonary edema et causa 
hypertension was found more in 
women. This is also in accordance 
with research from NHANES, that 
women at premenopause are at risk
The incidence is lower than 
that of men of the same age, but as 
they age women will have a higher 
Table 3.Distribution of patients with acute cardiogenic pulmonary edema et causa hypertension 
in the ER at UKI Hospital for the period January - November 2018 based on gender (N = 99)




The results of the study showed that 
the highest prevalence of cardiogenic 
acute pulmonary edema et causa 
hypertension was at the age of 56-65 
years as many as 41 people. (41%), while 
at the age 36 - 45 years as many as 8 
people (8%), aged 46 - 55 years as many 
as 20 patients (20%), and age more than 
66 years as many as 30 patients (30%).
Table 4. Age distribution of patients with acute cardiogenic pulmonary edema et causa hypertension
ER UKI Hospital for the period January - November 2018 based on age classification (N = 99).
AGE(YEAR) TOTAL (n) PERCENTAGE (%)
36 – 45 8 8
46 – 55 20 20
56 – 65 41 41
≥ 66 30 30
Total 99 99
The results in this study also indicate 
that the occurrence of acute pulmonary 
edema is due to hypertension (52%), 
coronary heart disease (42.6%), and 
other cardiovascular diseases (5.4%).
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Table 5. Distribution of causes of cardiogenic acute pulmonary edema 
in the ER at UKI Hospital for the period January - November 2018
Cause Total(n) Persentage (%)
Hypertension 51 52
Coronary artery Disease 42 42,6
Other cardiovascular Disease 6 5,4
Total 99 99
The results of other studies indicate 
that there is an increase in mortality 
in patients with cardiogenic acute 
pulmonary edema et causa hypertension 
in 8% or about 8 patients.
Conclusions and Recommendations
Acute cardiogenic pulmonary 
edema is one of the most common, 
detrimental and fatal diseases with a 
mortality rate of 8%. This occurs due 
to increased hydrostatic pressure in the 
pulmonary capillaries which results in 
increased transvascular fluid filtration. 
Generally, from studies of patients with 
acute pulmonary edema found in men 
and women, but tends to be more in 
women. Patient age is more common 
in the age of 56 - 65 years. Cardigenic 
acute pulmonary edema in this study 
was mostly caused by hypertension.
This research is expected to be a 
material for consideration and input 
to improve the quality and quality of 
health services, especially in reducing 
the incidence of hypertension through 
preventive action. The need for 
early detection and public awareness 
of hypertension is also important 
in preventing complications from 
hypertension.
In this study there are still many 
shortcomings and limitations. Therefore, 
it is necessary to carry out further 
research, especially on the risk factors 
for hypertension related to proper 
prevention in hypertension control 
programs in the community.
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